Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 29, Issue 3, 2002, Pages 235-250

  Tuk, Bert ^a   Van Gool, Toon ^a   Danhof, Meindert ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Allosteric modulation; Benzodiazepine BZ1 receptor; Electro encephalogram; PK PD modeling; Stimulus effect relationship

Indexed keywords

ALCOHOL; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BRETAZENIL; MIDAZOLAM; ZOLPIDEM;

ANIMAL EXPERIMENT; ARTICLE; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ELECTROENCEPHALOGRAPHY; MALE; MODEL; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

ANIMALS; BENZODIAZEPINONES; DRUG INTERACTIONS; ELECTROENCEPHALOGRAPHY; ETHANOL; MALE; MIDAZOLAM; MODELS, BIOLOGICAL; PROTEIN BINDING; PYRIDINES; RATS; RATS, WISTAR;

EID: 0036431712     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020202806759     Document Type: Article

References (35)

1. G. F. Koob, R. E. Strecker, and F. E. Bloom. Effects of naloxone on the anticonflict properties of alcohol and chlordiazepoxide. Subst. Alcohol Actions Misuse 1:447-457 (1980).
2. R. A. Deitrich, T. V. Dunwiddie, R. A. Harris, and V. G. Erwin. Mechanism of action of ethanol: Initial central nervous system actions. Pharmacol. Rev. 41:489-537 (1989).
3. A receptor ligands in Macaca fascicularis monkeys under different alcohol training conditions. Psychopharmacol. 152:181-188 (2000).
4. P. D. Suzdak, R. D. Schwartz, P. Skolnick, and S. M. Paul. Ethanol stimulates gammaaminobutyric acid receptor mediated chloride transport in rat brain synaptoneurosomes. Proc. Natl. Acad. Sci. USA 83:4071-4075 (1986).
5. A receptor channels. Annu. Rev. Neurosci. 17:569-602 (1994).
6. C. J. Rogers, R. E. Twyman, and R. L. Macdonald. Benzodiazepine and beta-carboline regulation of single GABAA receptor channels of mouse spinal neurones in culture. J. Physiol. Lond. 475:69-82 (1994).
7. W. Sieghart. Multiplicity of GABAA-benzodiazepine receptors. Trends. Pharmacol. Sci. 10:407-411 (1989).
8. S. M. Thompson. Modulation of inhibitory synaptic transmission in the hippocampus. Prog. Neurobiol. 42:575-609 (1994).
9. A receptor subtypes. Pharmacol. Rev. 47:181-234 (1995).
10. A receptors. Brain Res. Rev. 29: 196-217 (1999).
11. A receptors: Classification on the basis of subunit structure and receptor function. Pharmacol. Rev. 50:291-313 (1998).
12. P. Salva and J. Costa. Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic implications. Clin. Pharmacokin. 29:142-153 (1995).
13. B. Zivkovic, G. Perrault, E. Morel, and D. J. Sanger. Comparative pharmacology of zolpidem and other hypnotics and sleep inducers. In: Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach (J. P. Sauvenet, S. Z. Langer, and P. I. Morselli, eds.), pp. 97-109, Raven Press, New York (1988).
14. P. D. Nowell, S. Mazumdar, D. J. Buysse, M. A. Dew, C. F. Reynolds III, D. J. Kupfer. Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy. JAMA 278:2170-2177 (1997).
15. B. L. Lobo and W. L. Greene. Zolpidem: Distinct from triazolam? Ann. Pharmacother. 31:625-632 (1997).
16. C. R. Rush. Behavioral pharmacology of zolpidem relative to benzodiazepines: A review. Pharmacol. Biochem. Behav. 61:253-269 (1998).
17. M. Z. Mintzer and R. R. Griffiths. Triazolam and zolpidem: Effects on human memory and attentional processes. Psychopharmacology (Berl) 144:8-19 (1999).
18. M. Z. Mintzer and R. R. Griffiths. Selective effects of zolpidem on human memory functions. J. Psychopharmacot. 13:18-31 (1999).
19. W. E. Haefely, J. R. Martin, and P. Schoch. Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends. Pharmacol. Sci. 11:452-456 (1990).
20. J. R. Martin, L. Pieri, E. P. Bonetti, R. Schaffner, W. P. Burkard, R. Cumin, and W. E. Haefely. Ro 16-6028: A novel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry 21:360-362 (1988).
21. W. E. Haefely. Partial agonists of the benzodiazepine receptor: From animal data to results in patients. In: Chloride Channels and their Modulation by Neurotransmitters and Drugs (G. Biggio and E. Costa, eds.), pp. 275-292, Raven Press, New York (1988).
22. C. Hoyo-Vadillo, J. W. Mandema, and M. Danhof. Pharmacodynamic interaction between midazolam anda low dose of ethanol in vivo. Life Sci. 57:325-333 (1995).
23. B. Tuk, M. F. Van Oostenbruggen, V. M. M. Herben, J. W. Mandema, and M. Danhof. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: Midazolam and α-OH-midazolam. J. Pharmacol. Exp. Ther. 289:1067-1074 (1999).
24. B. Tuk, V. M. M. Herben, J. W. Mandema, and M. Danhof. Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. J. Pharmacol. Exp. Ther. 284:202-207 (1998).
25. B. Tuk, M. Danhof, and J. W. Mandema. The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates. J. Pharmacokinet. Biopharm. 25:39-62 (1997).
26. J. W. Mandema, M. T. Kuck, and M. Danhof. In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. J. Pharmacol. Exp. Ther. 261:56-61 (1992a).
27. T. K. Gregory and D. C. Pettus. An electroencephalographic processing algorithm specifically intended for analysis of cerebral electricaI activity. J. Clin. Monit. 2:190-197 (1986).
28. J. W. Mandema, M. T. Kuck, and M. Danhof. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. Br. J. Pharmacol. 105:164-170 (1992b).
29. J. W. Mandema, L. N. Sansom, M. C. Dios Vieitez, M. Hollander Jansen, and M. Danhof. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J. Pharmacol. Exp. Ther. 257:472-478 (1991).
30. M. Gibaldi and D. Perrier. Multi compartment models, in Pharmacokinetics, (Gibaldi, M. and Perrier, D., eds.) pp. 45-111, Marcel Dekker, New York (1982).
31. J. W. Mandema, E. Tukker, and M. Danhof. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: Midazolam and flumazenil. J. Pharmacol. Exp. Ther. 260:36-44 (1992c).
32. M. Danhof and J. W. Mandema. Modeling of the pharmacodynamics and pharmacodynamic interactions of CNS active drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. 30:516-519 (1992).
33. J. A. Dunbar, A. Penttila, and J. Pikkarainen. Drinking and driving: Choosing the legal limits. Br. Med. J. Clin. Res. Ed. 295:1458-1460 (1987).
34. E. M. Sellers, and M. R. Holloway. Drug kinetics and alcohol ingestion. Clin. Pharmacokin. 3:440-452 (1978).
35. J. W. Mandema and M. Danhof. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin. Pharmacokinet. 23:191-215 (1992d).